Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Phase 2

Completed

Conditions: Surgical Procedures

Interventions: Drug: GSK1278863
Drug: Placebo

First Posted Date: 2013-08-12

Last Posted Date: 2017-12-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 57

Registration Number: NCT01920594

Locations: 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada

A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors

Phase 3

Completed

Conditions: Fractures, Bone

Interventions: Biological: Denosumab 70 mg/mL
Drug: Zoledronic acid 4 mg
Drug: Placebo IV
Drug: Placebo SC
Dietary Supplement: Calcium supplement
Dietary Supplement: Vitamin D supplement

First Posted Date: 2013-08-12

Last Posted Date: 2017-01-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 487

Registration Number: NCT01920568

Locations: 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan

Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians

Completed

Conditions: Dermatitis, Atopic

First Posted Date: 2013-08-12

Last Posted Date: 2014-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 160

Registration Number: NCT01920464

Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy

Phase 2

Completed

Conditions: Atherosclerosis

Interventions: Drug: SB-480848 40 mg
Drug: SB-480848 80 mg
Drug: Placebo

First Posted Date: 2013-08-06

Last Posted Date: 2016-12-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 103

Registration Number: NCT01916720

A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis

Phase 4

Completed

Conditions: Skin Diseases

Interventions: Drug: Fluticasone propionate

First Posted Date: 2013-08-05

Last Posted Date: 2018-10-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 107

Registration Number: NCT01915914

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: 1% clindamycin phosphate gel
Drug: Duac™Once Daily Gel

First Posted Date: 2013-08-05

Last Posted Date: 2017-02-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1018

Registration Number: NCT01915732

Locations: 🇨🇳
GSK Investigational Site, Wuhan, China

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Phase 4

Completed

Conditions: Rhinitis, Allergic, Perennial and Seasonal

Interventions: Drug: Cetirizine Placebo
Drug: FPNS
Drug: FPNS Placebo
Drug: Cetirizine

First Posted Date: 2013-08-05

Last Posted Date: 2018-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 682

Registration Number: NCT01916226

Locations: 🇺🇸
GSK Investigational Site, Greenfield, Wisconsin, United States

W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: clindamycin1%/tretinoin 0.025% gel
Drug: vehicle gel

First Posted Date: 2013-08-05

Last Posted Date: 2017-07-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 64

Registration Number: NCT01915758

Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients

Phase 4

Withdrawn

Conditions: Depressive Disorder

Interventions: Drug: Paroxetine CR

First Posted Date: 2013-08-05

Last Posted Date: 2014-07-16

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT01916200

Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination

Completed

Conditions: Infections, Rotavirus

Interventions: Other: Data interpretation

First Posted Date: 2013-08-05

Last Posted Date: 2014-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01915888

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy